Optimind Pharma, a Canada-based psychedelic therapy provider, has raised USD 0.5 million in a private placement by issuing 10 million common shares at USD 0.05 per share.
The new funds will be used toward working capital purposes.
Optimind Pharma is a provider of psychedelic therapies, specializing in prescribing medical cannabis, ketamine-assisted treatment, and other psychedelic-enhanced psychotherapy modalities for treating post-traumatic stress disorder, anxiety, depression, and other mental illnesses and disabilities.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.